Skip to main content
Assets
AbbVie logo
ABBV.NYSE
AbbVie
Health Care · Biotechnology

Biopharmaceutical company discovering and developing advanced therapies for immunology, oncology, neuroscience, and eye care including Humira.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for AbbVie.

Historical AI Opinions

AbbVie Inc. (ABBV.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 12 advisor reports and comparisons.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ThinkerAdvisor config deprecated

Investment Expert AI

Investment framework Framework

Model rating

Buy

5-Year Return Est.

+58.6%

Includes 1.79% annual net dividend contribution

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.78.66147.33215.99284.66353.32Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$239+4.8%Not Generated this time
$250+9.6%Not Generated this time
$261+14.7%Not Generated this time
$273+19.8%Not Generated this time
$285+25.2%Not Generated this time
$296+30.2%Not Generated this time
$306+34.4%Not Generated this time
$316+38.7%Not Generated this time
$323+42.0%Not Generated this time
$330+45.1%Not Generated this time
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

The most reasonable thesis projects AbbVie successfully navigating the post-Humira era with mid-to-high single-digit revenue growth. Skyrizi and Rinvoq are expected to meet consensus estimates, becoming the dominant standard of care in their respective indications. The aesthetics business stabilizes and grows in line with global GDP, while the neuroscience portfolio provides durable, diversified cash flow. The company maintains its Dividend Aristocrat status, appealing to income-oriented investors, which provides a floor for the stock price. Valuation multiples remain stable or expand slightly as the market gains confidence in the long-term pipeline, resulting in steady capital appreciation supplemented by a reliable dividend yield.

2. Scenarios & Signals

2.1. Bull Case

In the bull case, AbbVie's immunology duo, Skyrizi and Rinvoq, significantly outperforms peak sales estimates, collectively exceeding $30 billion annually by 2027, effectively rendering the Humira loss of exclusivity negligible. The aesthetics portfolio (Botox) sees a resurgence driven by a robust global consumer economy, while the neuroscience division, bolstered by the integration of recent acquisitions like Cerevel Therapeutics, delivers blockbuster readouts in schizophrenia and Parkinson's disease. Furthermore, successful entry into the obesity or metabolic space through internal R&D or strategic bolt-on acquisitions triggers a valuation re-rating, expanding the P/E multiple closer to high-growth pharma peers. Macroeconomic tailwinds, such as lower interest rates, reduce debt servicing costs from past M&A, allowing for aggressive dividend hikes and share buybacks.

2.2. Bear Case

The bear case envisions a scenario where the Inflation Reduction Act (IRA) Medicare price negotiations impact AbbVie's portfolio more severely than anticipated, specifically targeting Imbruvica and eventually Skyrizi earlier than modeled. Pricing pressure in the US immunology market intensifies due to aggressive contracting by PBMs and competition from newer mechanisms of action. The aesthetics division suffers from prolonged consumer spending weakness, dragging down the high-margin Botox franchise. Additionally, pipeline setbacks in the oncology solid tumor program and integration difficulties with recent acquisitions lead to stagnant earnings growth. Under these conditions, the market compresses AbbVie's valuation multiple to historic lows (8-10x P/E), focusing on the lack of a clear successor to the current growth drivers.

4. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 516Thinking Tokens: 1,753Response Tokens: 7,188Total Tokens: 9,457
Thinker modeThinker · no external search

This Thinker run did not use external web search. The model relied on the supplied research context and its internal reasoning.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    Input Prompt Market Equity Balanced System Instruction Driven Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

  2. 02

    Global context in this run

    Not used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Forecast output requested

    Output Json Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.